MCMelissa Victoria Chan

Melissa Victoria Chan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Melissa Victoria Chan has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Factors that modulate platelet reactivity as measured by 5 assay platforms in 3429 individuals

    by Melissa V. Chan, Ming-Huei Chen, Florian Thibord, Bongani B. Nkambule, Amber R. Lachapelle, Joseph Grech, Zoe E. Schneider, Catherine Wallace de Melendez, Jennifer E. Huffman, Melissa A. Hayman, et al.


  • Trends among platelet function, arterial calcium, and vascular function measures

    by Jason Cunha, Melissa V. Chan, Bongani B. Nkambule, Florian Thibord, Amber Lachapelle, Robin E. Pashek, Ramachandran S. Vasan, Jian Rong, Emelia J. Benjamin, Naomi M. Hamburg, et al.

    Platelet reactivity measures can be useful in cardiovascular disease (CVD) risk determination. For example, Berger et al. found that adenosine diphosphate (ADP) and trimethylamine N-oxide-induced p...


  • Open Access

    Serotonin‐Affecting Antidepressant Use in Relation to Platelet Reactivity

    by Joseph Grech, Melissa Victoria Chan, Chinedu Ochin, Amber Lachapelle, Florian Thibord, Zoe Schneider, Bongani Brian Nkambule, Paul Charles John Armstrong, Catherine Wallace de Melendez, Katherine L. Tucker, et al.

    Depression is an independent risk factor of cardiovascular disease morbidity. Serotonin is a key neurotransmitter in depressive pathology, contained within platelets, and is a weak activator of platelets. Our study assessed the link between platelet reactivity traits, depression, and antidepressant (AD) use in a large population sample. Our study was conducted in the Framingham Heart Study (n = 3,140), and AD use (n = 563) and aspirin use (n = 681) were noted. Depression was measured using the Center for Epidemiological Studies‐Depression (CES‐D) survey. Platelet reactivity traits were measured across multiple agonists using five distinct assays. We utilized a linear mixed effects model to test associations between platelet traits and depression, adjusting for age, sex, aspirin use, and AD use. Similarly, we analyzed trait associations with any AD use, serotonin‐affecting ADs, and norepinephrine‐affecting ADs, respectively. There were strong associations with reduced platelet function and AD use, particularly with serotonin‐affecting medications. This included lower Optimul epinephrine maximal aggregation (P = 4.87E‐13), higher U46619 half maximal effective concentration (P = 9.09E‐11), lower light transmission aggregometry (LTA) adenosine diphosphate (ADP) final aggregation (P = 1.03E‐05), and higher LTA ADP disaggregation (P = 2.28E‐05). We found similar associations with serotonin‐affecting ADs in an aspirin‐taking subset of our sample. There were no significant associations between platelet traits and depression. In the largest study yet of AD use and platelet function we show that antidepressants, particularly serotonin‐affecting ADs, inhibit platelets. We did not find evidence that depressive symptomatology in the absence of medication is associated with altered platelet function. Our results are consistent with AD use leading to platelet serotonin depletions, decreased stability of platelet aggregates, and overall decreased aggregation to multiple agonists, which may be a mechanism by which ADs increase risk of bleeding and decrease risk of thrombosis.


  • Open Access

    Neutrophil-Derived Protein S100A8/A9 Alters the Platelet Proteome in Acute Myocardial Infarction and Is Associated With Changes in Platelet Reactivity

    by Abhishek Joshi, Lukas E. Schmidt, Sean A. Burnap, Ruifang Lu, Melissa V. Chan, Paul C. Armstrong, Ferheen Baig, Clemens Gutmann, Peter Willeit, Peter Santer, et al.

    Objective: Platelets are central to acute myocardial infarction (MI). How the platelet proteome is altered during MI is unknown. We sought to describe changes in the platelet proteome during MI and identify corresponding functional consequences. Approach and Results: Platelets from patients experiencing ST-segment–elevation MI (STEMI) before and 3 days after treatment (n=30) and matched patients with severe stable coronary artery disease before and 3 days after coronary artery bypass grafting (n=25) underwent quantitative proteomic analysis. Elevations in the proteins S100A8 and S100A9 were detected at the time of STEMI compared with stable coronary artery disease (S100A8: FC, 2.00; false discovery rate, 0.05; S100A9: FC, 2.28; false discovery rate, 0.005). During STEMI, only S100A8 mRNA and protein levels were correlated in platelets ( R =0.46, P =0.012). To determine whether de novo protein synthesis occurs, activated platelets were incubated with 13C-labeled amino acids for 24 hours and analyzed by mass spectrometry. No incorporation was confidently detected. Platelet S100A8 and S100A9 was strongly correlated with neutrophil abundance at the time of STEMI. When isolated platelets and neutrophils were coincubated under quiescent and activated conditions, release of S100A8 from neutrophils resulted in uptake of S100A8 by platelets. Neutrophils released S100A8/A9 as free heterodimer, rather than in vesicles or extracellular traps. In the community-based Bruneck study (n=338), plasma S100A8/A9 was inversely associated with platelet reactivity—an effect abrogated by aspirin. Conclusions: Leukocyte-to-platelet protein transfer may occur in a thromboinflammatory environment such as STEMI. Plasma S100A8/A9 was negatively associated with platelet reactivity. These findings highlight neutrophils as potential modifiers for thrombotic therapies in coronary artery disease.


  • Open Access

    Platelet inhibition by P2Y12 antagonists is potentiated by adenosine signalling activators

    by Chih‐Chin Shih, Melissa V. Chan, Nicholas S. Kirkby, Ivana Vojnovic, Jane A. Mitchell, Paul C. Armstrong, Timothy D. Warner

    Background and Purpose: P2Y12 receptor antagonists reduce platelet aggregation and the incidence of arterial thrombosis. Adenosine signalling in platelets directly affects cyclic nucleotide tone, which we have shown to have a synergistic relationship with P2Y12 inhibition. Several studies suggest that ticagrelor inhibits erythrocyte uptake of adenosine and that this could also contribute to its antiplatelet effects. We therefore examined the effects on platelet activation of adenosine signalling activators in combination with the P2Y12 receptor antagonists ticagrelor and prasugrel.Experimental Approach: Human washed platelets, platelet‐rich plasma and whole blood were used to test the interactions between ticagrelor or prasugrel and adenosine or 5′‐N‐ethylcarboxamidoadenosine (NECA). Platelet reactivity to thrombin, protease‐activated receptor 1 (PAR‐1) activation or collagen was assessed by a combination of 96‐well plate aggregometry, light transmission aggregometry, whole blood aggregometry, ATP release assay and levels of cAMP.Key Results: The inhibitory effects of ticagrelor and prasugrel on platelet aggregation and ATP release were enhanced in the presence of adenosine or NECA. Isobolographic analysis indicated a powerful synergy between P2Y12 receptor inhibition and adenosine signalling activators. Increased levels of cAMP in platelets were also observed. In all cases, ticagrelor showed similar synergistic effects on platelet inhibition as prasugrel in the presence of adenosine or NECA.Conclusion and Implications: These results indicate that P2Y12 antagonists have a synergistic relationship with adenosine signalling and that their efficacy may depend partly upon the presence of endogenous adenosine. This effect was common for prasugrel and ticagrelor despite reports of differences in their effects upon adenosine reuptake.


  • Open Access

    Platelet Reactivity in Individuals Over 65 Years Old Is Not Modulated by Age

    by Melissa V. Chan, Ming-Huei Chen, Temo Barwari, Jennifer E. Huffman, Paul Charles Armstrong, Shih-Jen Hwang, Peter Santer, Brigitte Wierer, Manuel Mayr, Stefan Kiechl, et al.


  • Open Access

    Loss of GPVI and GPIbα contributes to trauma-induced platelet dysfunction in severely injured patients

    by Paul Vulliamy, Samantha J. Montague, Scarlett Gillespie, Melissa V. Chan, Lucy A. Coupland, Robert K. Andrews, Timothy D. Warner, Elizabeth E. Gardiner, Karim Brohi, Paul C. Armstrong

    Trauma-induced coagulopathy (TIC) is a complex, multifactorial failure of hemostasis that occurs in 25% of severely injured patients and results in a fourfold higher mortality. However, the role of platelets in this state remains poorly understood. We set out to identify molecular changes that may underpin platelet dysfunction after major injury and to determine how they relate to coagulopathy and outcome. We performed a range of hemostatic and platelet-specific studies in blood samples obtained from critically injured patients within 2 hours of injury and collected prospective data on patient characteristics and clinical outcomes. We observed that, although platelet counts were preserved above critical levels, circulating platelets sampled from trauma patients exhibited a profoundly reduced response to both collagen and the selective glycoprotein VI (GPVI) agonist collagen-related peptide, compared with those from healthy volunteers. These responses correlated closely with overall clot strength and mortality. Surface expression of the collagen receptors GPIbα and GPVI was reduced on circulating platelets in trauma patients, with increased levels of the shed ectodomain fragment of GPVI detectable in plasma. Levels of shed GPVI were highest in patients with more severe injuries and TIC. Collectively, these observations demonstrate that platelets experience a loss of GPVI and GPIbα after severe injury and translate into a reduction in the responsiveness of platelets during active hemorrhage. In turn, they are associated with reduced hemostatic competence and increased mortality. Targeting proteolytic shedding of platelet receptors is a potential therapeutic strategy for maintaining hemostatic competence in bleeding and improving the efficacy of platelet transfusions.


  • Open Access

    Combination of cyclic nucleotide modulators with P2Y12 receptor antagonists as anti‐platelet therapy

    by Paul C. Armstrong, Plinio M. Ferreira, Melissa V. Chan, Martina H. Lundberg Slingsby, Marilena Crescente, Chih‐Chin Shih, Nicholas S. Kirkby, Adrian J. Hobbs, Timothy D. Warner


  • Open Access

    Inhibition of profibrotic microRNA-21 affects platelets and their releasate

    by Temo Barwari, Seda Eminaga, Ursula Mayr, Ruifang Lu, Paul C. Armstrong, Melissa V. Chan, Mahnaz Sahraei, Marta FernánDez-Fuertes, Thomas Moreau, Javier Barallobre-Barreiro, et al.

    Fibrosis is a major contributor to organ disease for which no specific therapy is available. MicroRNA-21 (miR-21) has been implicated in the fibrogenetic response, and inhibitors of miR-21 are currently undergoing clinical trials. Here, we explore how miR-21 inhibition may attenuate fibrosis using a proteomics approach. Transfection of miR-21 mimic or inhibitor in murine cardiac fibroblasts revealed limited effects on extracellular matrix (ECM) protein secretion. Similarly, miR-21–null mouse hearts showed an unaltered ECM composition. Thus, we searched for additional explanations as to how miR-21 might regulate fibrosis. In plasma samples from the community-based Bruneck Study, we found a marked correlation of miR-21 levels with several platelet-derived profibrotic factors, including TGF-β1. Pharmacological miR-21 inhibition with an antagomiR reduced the platelet release of TGF-β1 in mice. Mechanistically, Wiskott-Aldrich syndrome protein, a negative regulator of platelet TGF-β1 secretion, was identified as a direct target of miR-21. miR-21–null mice had lower platelet and leukocyte counts compared with littermate controls but higher megakaryocyte numbers in the bone marrow. Thus, to our knowledge this study reports a previously unrecognized effect of miR-21 inhibition on platelets. The effect of antagomiR-21 treatment on platelet TGF-β1 release, in particular, may contribute to the antifibrotic effects of miR-21 inhibitors.


  • Open Access

    Not all light transmission aggregation assays are created equal: qualitative differences between light transmission and 96-well plate aggregometry

    by Melissa V. Chan, Philip D. Leadbeater, Steve P. Watson, Timothy D. Warner

    In this short article, submitted as part of the review on platelet function testing, we illustrate the quantitative and qualitative differences between classical light transmission aggregometry (LTA) and 96-well plate aggregometry. We show that responses to platelet agonists and antagonists differ depending upon the method of aggregation testing. For example, in 96-well aggregometry, responses to collagen are strongly inhibited by P2Y12 receptor antagonists while in LTA they are much less affected. Furthermore, we explore the importance of differences in the mechanical environment upon platelet aggregation. We emphasize that LTA and 96-well aggregometry are not interchangeable assays. These two assays are best used as complementary tests to explore platelet function in depth.